From regulatory approval, to investments, to getting coverage from insurance companies, it’s hard out there for a digital therapeutics manufacturer—but developers have found some unique pathways that work in their favor.
With the recent bankruptcy of former DTX leader Pear Therapeutics, the question of DTX payment is always top of mind for the developer